BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 19222642)

  • 1. Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients.
    Ghaith F; Abdou S; El-Bendary A; Shahin D; Eid M; Megeed WA; El-Sheikh I; Farrag W; Yousuf S
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):103-12. PubMed ID: 19222642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
    Aoun P; Wiggins M; Pickering D; Foran J; Rasheed H; Pavletic SZ; Sanger W
    Cancer Genet Cytogenet; 2004 Oct; 154(2):138-43. PubMed ID: 15474149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
    Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
    Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of SOCS-1 mRNA expression by RT-PCR in the patients with myeloid leukemia].
    Yang HP; Dai M; Zhou HS; Huang L; Zhang DH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):677-80. PubMed ID: 16928298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha.
    Roman-Gomez J; Jimenez-Velasco A; Castillejo JA; Cervantes F; Barrios M; Colomer D; Heiniger A; Torres A
    Haematologica; 2004 Jan; 89(1):42-8. PubMed ID: 14754605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T; Bumm T; Otto S; Al-Ali HK; Kovacs I; Krug D; Köhler T; Krahl R; Niederwieser D; Deininger MW
    Haematologica; 2004 Jan; 89(1):49-57. PubMed ID: 14754606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of FHIT expression in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
    Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the genesis and prognosis of variant translocations in chronic myeloid leukemia.
    Gorusu M; Benn P; Li Z; Fang M
    Cancer Genet Cytogenet; 2007 Mar; 173(2):97-106. PubMed ID: 17321324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
    Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.